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Abstract
 
Oxidation of low density lipoprotein (LDL) generates a variety of oxidatively modified lipids
and lipid-protein adducts that are immunogenic and proinflammatory, which in turn contribute
to atherogenesis. Cells undergoing apoptosis also display oxidized moieties on their surface
membranes, as determined by binding of oxidation-specific monoclonal antibodies. In the
present paper, we demonstrated by mass spectrometry that in comparison with viable cells,
membranes of cells undergoing apoptosis contain increased levels of biologically active oxidized
phospholipids (OxPLs). Indeed, immunization of mice with syngeneic apoptotic cells induced
high autoantibody titers to various oxidation-specific epitopes of oxidized LDL, including OxPLs
containing phosphorylcholine, whereas immunization with viable thymocytes, primary necrotic
thymocytes, or phosphate-buffered saline did not. Reciprocally, these antisera specifically
bound to apoptotic cells through the recognition of oxidation-specific epitopes. Moreover,
splenocyte cultures from mice immunized with apoptotic cells spontaneously released significant
levels of T helper cell (Th) 1 and Th2 cytokines, whereas splenocytes from controls yielded
only low levels. Finally, we demonstrated that the OxPLs of apoptotic cells activated endothelial
cells to induce monocyte adhesion, a proinflammatory response that was abrogated by an anti-
body specific to oxidized phosphatidylcholine. These results suggest that apoptotic cell death
generates oxidatively modified moieties, which can induce autoimmune responses and a local
inflammatory response by recruiting monocytes via monocyte–endothelial cell interaction.
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Introduction
 
Apoptotic cells have been increasingly recognized as targets
of autoantibodies that arise in a broad spectrum of autoim-
mune diseases. The evidence that apoptotic cells are targeted
by autoantibodies was provided by studies showing that au-
toantibodies from humans and mice with systemic lupus
erythematosus (SLE) recognize autoantigens that are prom-
inently clustered in the surface blebs of apoptotic cells (1,
2). Several studies have also demonstrated that antiphos-
pholipid antibodies (aPLs), which arise in a variety of autoim-
mune disorders such as the primary aPL syndrome and
SLE, recognize the plasma membranes of apoptotic cells,
but not viable cells (3, 4). In addition, mice immunized
with syngeneic apoptotic cells have been shown to generate
autoantibodies to apoptotic cells and cellular components,
such as ssDNA and cardiolipin (5), implying that apoptotic
cells not only serve as targets for antibodies but also provide
autoantigens that trigger autoimmune responses. More-
over, evidence suggests that defective clearance and, hence,
abnormal accumulation of apoptotic cells may contribute
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to such autoimmune response (6, 7). However, the exact
molecular nature of the antigenic determinants or immu-
nostimulatory molecules that induce such autoimmune re-
sponse remains elusive.
Atherosclerosis is now considered a chronic inflamma-
tory disease of the vascular wall; in addition, immune
mechanisms modulate its progression (8, 9). Oxidized low
density lipoprotein (Ox[LDL]) has been demonstrated to
play a key role in atherogenesis because of its proinflamma-
tory and immunogenic properties (10, 11). Oxidation of
LDL generates a variety of oxidatively modified lipids and
lipid-protein adducts. For example, when polyunsaturated
fatty acids in phospholipids of LDL undergo peroxidation,
reactive decomposition products, such as the oxidized
phospholipid (OxPL) backbone and malondialdehyde (MDA)
are formed. These products can covalently modify pro-
tein and lipid moieties in LDL, leading to formation of
neoself-epitopes, which we have termed “oxidation-spe-
cific” neoepitopes and demonstrated to be highly immuno-
genic (11). Antibodies to these oxidation-specific epitopes
can be found in humans as well as in mice. We docu-
mented previously that hypercholesterolemic apolipopro-
tein E–deficient (
 
apoE
 
   
 
) mice with atherosclerosis have
robust antibody titers to OxLDL (12). Using copper Ox-
LDL or MDA-modified LDL (MDA-LDL) as selecting an-
tigens, we cloned monoclonal IgM autoantibodies to oxi-
dation-specific epitopes of OxLDL from the spleens of
naive 
 
apoE
 
   
 
 mice, termed EO antibodies (13). Previous
studies have shown that these monoclonal anti-OxLDL an-
tibodies, such as the prototypic EO6, also recognize the
plasma membranes of apoptotic cells but not viable cells
(14), implying that some oxidation-specific epitopes on
OxLDL are also present on membranes of cells undergoing
apoptosis, which are known to be under increased oxida-
tive stress. EO6 can block the uptake of OxLDL by macro-
phage scavenger receptors (15), and especially CD36 (16).
Similarly, EO6 partially blocks the uptake of apoptotic cells
by macrophages, implying that such OxPLs are ligands me-
diating apoptotic cell clearance as well (14). Indeed, Hazen
et al. have demonstrated that a variety of phosphorylcho-
line (PC)-containing OxPLs are CD36 ligands (17).
Of considerable interest, EO6 has been demonstrated re-
cently to be identical to highly conserved T15 clonospe-
cific natural antibodies specific for PC (18). These T15
antibodies recognize PC as a component of the capsular
polysaccharide of microorganisms, such as 
 
Streptococcus pneu-
moniae
 
, and participate in the innate immune response
to microorganisms in mice (19). We have shown previ-
ously that EO6/T15 bind to OxPLs containing the PC
headgroup, such as 1-palmitoyl-2-(5-oxovaleroyl)-sn-glyc-
ero-3-PC (POVPC), but did not bind to native, nonoxi-
dized phosphatidylcholines even though they contained the
same PC moiety (15, 18, 20). Thus, the PC headgroup is a
cryptic epitope of phosphatidylcholine in native LDL or
viable cell membranes, and the PC epitope becomes acces-
sible for binding by these anti-PC antibodies after oxi-
dation-induced conformational changes occur in the phos-
phatidylcholine molecule in OxLDL or apoptotic cells. In
point of fact, it is the PC head group of aldol condensates
of POVPC dimers, trimers, or larger aggregates that ap-
pears to be the actual epitope of free POVPC (20).
In the present paper, we demonstrate that immunization
of mice with syngeneic apoptotic cells induced humoral im-
mune responses to oxidation-specific epitopes of OxLDL
and apoptotic cells. In addition, we demonstrate that cells
undergoing apoptosis contain increased levels of biologically
active OxPLs and that these apoptotic cells activate endothe-
lial cells to induce monocyte adhesion, which can be
blocked by EO6. These data indicate that cells undergoing
apoptosis generate oxidation-specific neoepitopes, including
biologically active OxPLs, which in turn serve as dominant
autoantigens as well as provide “proinflammatory” signals,
mediating autoimmune and inflammatory responses.
 
Materials and Methods
 
Mice and Cell/Immunogen Preparation. 
 
All experimental pro-
tocols were approved by the Animal Subjects Committee at the
University of California, San Diego. Thymocytes were isolated
from 4–6-wk-old National Institutes of Health (NIH)/Swiss-
Webster and C57BL/6 mice (Harlan Sprague Dawley, Inc.). To
obtain apoptotic cells, thymocytes were incubated with 1 
 
 
 
M
dexamethasone (Sigma-Aldrich) or 50 ng/ml PMA (Sigma-Ald-
rich) in RPMI 1640/10% FCS for 15 h. Under these conditions,
 
 
 
80% of thymocytes have undergone apoptosis as judged by an-
nexin V binding and among this population, 
 
 
 
60% of thymocytes
express oxidation-specific epitopes on their surface membranes as
determined by binding of EO6 or EO14, which are autoantibod-
ies specific for OxLDL and MDA-LDL, respectively (13). The ap-
optotic thymocytes were harvested and washed twice with PBS
before the use. For monocyte adhesion and chemokine assays, we
used serum deprivation for 18 h or UV irradiation (20 mJ/cm
 
2
 
) to
generate apoptotic thymocytes, which also express OxPLs, as de-
termined by EO6 binding (unpublished data).
 
Lipid Extraction and Analysis by Mass Spectrometry. 
 
Total lip-
ids were extracted from thymocytes by chloroform/methanol as
described previously (15, 21). The OxPLs in these lipids extracts
were analyzed by liquid chromatography multiple reaction moni-
toring (LC/MRM) as described previously (21). A detailed de-
scription of these procedures can be found in the online supple-
mental Materials and Methods (available at http://www.jem.org/
cgi/content/full/jem.20031763/DC1).
 
Immunization Protocol.
 
Three groups of 10-wk-old NIH/
Swiss-Webster mice were immunized in the presence of adjuvant
with the following: (a) PBS, (b) viable thymocytes, or (c) dexa-
methasone-treated thymocytes. 100 
 
 
 
l of 20 
 
 
 
 10
 
6
 
 thymocytes in
PBS or PBS alone was mixed with an equal volume of Freund’s
adjuvant, and used to immunize each mouse. For primary immu-
nization, immunogens with CFA were injected subcutaneously
into the inguinal area, whereas booster immunizations were given
with IFA by i.p. injection 2, 4, and 6 wk after the primary. Plasma
samples were obtained immediately before primary immuniza-
tions and 1 wk after final booster immunizations.
Four groups of 10-wk-old C57BL/6 mice were also immu-
nized in the absence of adjuvant with the following: (a) PBS, (b)
viable thymocytes, (c) dexamethasone-treated thymocytes, or (d)
necrotic thymocytes. The primary necrotic thymocytes were
generated by three cycles of freezing and thawing of initially via-
ble cells. After the final thaw, the entire cell mixture was sus- 
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pended in PBS. Each immunogen was injected i.p. every 2 wk
for 8 wk. Plasma samples were obtained as described before.
 
Chemiluminescent Immunoassay. 
 
Titers of autoantibodies in
murine sera to oxidation-specific epitopes were determined using
a chemiluminescent enzyme immunoassay as described in online
supplemental Materials and Methods.
 
Competition Immunoassay. 
 
Pooled or representative immune
sera from mice immunized with apoptotic cells were diluted in
PBS containing 1% BSA and incubated with increasing concen-
trations of indicated competitors for 18 h at 4
 
 
 
C, and the binding
to OxLDL was determined by chemiluminescent immunoassay.
The apparent binding affinities of the IgG and the avidity of IgM
(22) of the antiserum to OxLDL were determined by competitive
inhibition assay to calculate the dissociation constants (K
 
d
 
s) of an-
tibodies according to the Klotz method (MW of apoB 
 
 
 
500,000; reference 23). Calculations are based on the concentra-
tion of soluble OxLDL at which binding of antiserum to immo-
bilized OxLDL was inhibited by 
 
 
 
50%. To demonstrate specific-
ity of immune sera binding to apoptotic cells through recognition
of oxidation-specific epitopes, immune sera diluted in 1% BSA/
PBS were preabsorbed as described before. Immune complexes
were pelleted, and supernatants were tested for remaining bind-
ing activity to apoptotic cells by flow cytometry analysis.
 
Immunofluorescence Microscopy and Flow Cytometry Analysis.
 
Normal, viable thymocytes or dexamethasone-induced apoptotic
thymocytes were harvested and incubated with immune sera di-
luted in 1% BSA/PBS (buffer A) for 30 min at 4
 
 
 
C. After the incu-
bation, cells were washed and incubated with 15 
 
 
 
g/ml of fluores-
cein-conjugated F(ab)
 
2
 
 fragments against mouse IgM or IgG
(Jackson ImmunoResearch Laboratories) in buffer A for 30 min
and then washed. For immunofluorescence microscopy study, cells
were incubated with 1 
 
 
 
g/ml of Hoechst dye (Sigma-Aldrich) for
10 min, fixed with 2% paraformaldehyde, and spun down on glass
slides using cytospin (ThermoShandon). Images were captured by
deconvolution microscopy using a DeltaVision deconvolution mi-
croscopic system operated by SoftWorx software (Applied Preci-
sion). For flow cytometry analysis, cells were incubated with 1 
 
 
 
g/
ml of propidium iodide (PI) for 10 min and immediately analyzed
by a FACScan instrument (Becton Dickinson). Data from each ex-
periment were analyzed using CELLQuest software.
 
Splenocyte Culture and Cytokine Assay. 
 
3 d before sacrifice,
mice were boosted i.p. with the respective immunogens without
Freund’s adjuvant. Splenocytes from the mice were taken up in
DME with 10% FCS, 10 mM Hepes, and 2 mM gentamycin, and
seeded at 5 
 
 
 
 10
 
5
 
 nucleated cells per well into 96-well tissue cul-
ture plates (Falcon). After 72 h of incubation, the levels of cyto-
kines in cell culture supernatants were determined by chemilu-
minescent immunoassays using matched monoclonal capturing
antibodies and biotinylated detecting antibodies against murine cy-
tokines according to the manufacturer’s protocol (R&D Systems).
 
Monocyte Adhesion Assay. 
 
Monocyte adhesion assay was per-
formed as described previously (24). In brief, porcine aortic en-
dothelial cells (PAECs) or human coronary artery endothelial
cells (HCAECs) were cultured in 48-well tissue culture plates in
medium 199 supplemented with 15% FCS and antibiotics until
confluent. Stimulants (normal, viable thymocytes, apoptotic thy-
mocytes, or LPS) were added to each well with confluent endo-
thelial cells and incubated for 4 h at 37
 
 
 
C. After the incubation of
stimulants with endothelial cells, stimulants were removed and
endothelial cells were washed six times with PBS. THP-1 cells (a
monocyte-like cell line) in RPMI 1640 medium with 10% FCS
were seeded at 10
 
5
 
 cells per well and incubated for 30 min at
37
 
 
 
C. Wells were washed gently to remove all but the firmly ad-
herent THP-1 cells. The number of adherent THP-1 cells was
determined in a 10
 
 
 
 high-power field per well.
 
Flow Cytometry and Chemokine Assays. 
 
HCAECs were cul-
tured in 6-well or 96-well tissue culture plates for flow cytometry
and chemokines assays, respectively, and confluent HCAECs
were treated with complete culture media alone or apoptotic
thymocytes as stimulant for 4 h at 37
 
 
 
C in the complete culture
media. For flow cytometry analyses, HCAECs were harvested
with EDTA and stained with antibodies against ICAM, VCAM,
E-selectin, or CS-1 fibronectin (BD Biosciences) and analyzed
using flow cytometry as described before. For chemokine analy-
sis, the culture supernatants were collected and assayed for IL-8
protein levels (R&D Systems) as described before.
 
Online Supplemental Material. 
 
Procedures for lipid extraction
from cells and for analysis of these lipids extracts by LC/MRM, as
well as detailed methods for chemiluminescent immunoassays
are available in online supplemental material available at http://
www.jem.org/cgi/content/full/jem.20031763/DC1.
 
Results
 
Cells Undergoing Apoptosis Generate Proinflammatory
OxPLs.
 
We showed previously that apoptotic cells are rec-
ognized by monoclonal autoantibody EO6, which specifi-
cally recognizes the PC moiety of OxPLs, such as POVPC
and 1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-PC (PEIPC),
as well as by antibody EO14, which recognizes MDA-modi-
fied epitopes (14). These recent observations suggested that
membranes of apoptotic cells contain apoptotic cell–associ-
ated molecular patterns (7) that are derived from phospho-
lipid oxidation. To definitively identify PC-containing Ox-
PLs in membranes of cells undergoing apoptosis, we analyzed
lipid fractions extracted from normal and apoptotic thy-
mocytes by LC/MRM. Consistent with the immunologic
characterization, lipid fractions of dexamethasone or PMA-
treated apoptotic thymocytes had a significantly increased
content of biologically active OxPLs including POVPC,
Figure 1. LC/MRM analysis of OxPLs from cellular lipid extracts.
Quantification of OxPLs obtained from lipid extracts of viable or apoptotic
thymocytes induced either by dexamethasone (DEXA) or by PMA treatment
was performed using LC/MRM. POVPC, 1-palmitoyl-2-(5-oxovaleroyl)-
sn-glycero-3-PC; PGPC, 1-palmitoyl-2-glutaroyl-sn-glycero-3-PC; PEIPC,
1-palmitoyl-2-epoxyisoprostane-sn-glycero-3-PC; lyso-PC, 1-palmitoyl-
2-lyso-sn-glycero-3-PC. Amounts of the four OxPLs were determined
using 1,2-dimyristoyl-sn-glycero-3-PC as a standard. Data are expressed
as micrograms per milligram of the parent lipid 1-palmitoyl-2-arachidonyl-
sn-glycero-3-phosphorylcholine (PAPC)   SD from three separate ex-
tractions. *, P   0.001 compared with viable thymocytes. 
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PEIPC, 1-palmitoyl-2-glutaroyl-sn-glycero-3-PC, and 1-pal-
mitoyl-2-lyso-sn-glycero-3-PC (lyso-PC) compared with lipid
fractions from viable thymocytes (Fig. 1). As we have shown
recently that EO6 and EO14 recognize surface membrane
determinants that newly arise on apoptotic cells (14), the cur-
rent data indicate that apoptotic cells contain increased levels
of these oxidized moieties, which may also have redistributed
to facilitate their immune recognition.
 
Normal Mice Immunized with Syngeneic Apoptotic Thymocytes
Develop Autoantibodies against Oxidation-specific Epitopes.
 
To
determine whether these stress-induced oxidation-specific
epitopes on apoptotic cells could induce specific immune
responses, we immunized NIH/Swiss-Webster mice with
syngeneic apoptotic thymocytes emulsified in Freund’s
adjuvant. After the final boost, plasma was obtained and
tested for antibody binding to several models of oxida-
tion-specific epitopes, including copper OxLDL, POVPC-
modified LDL (POVPC-LDL), and MDA-modified LDL
(MDA-LDL). As seen in Fig. 2, all mice immunized with
apoptotic cells developed high IgM and high IgG titers to
oxidation-specific epitopes of OxLDL. Moreover, mice
immunized with apoptotic cells also developed IgM (Fig. 2
A) and to a lesser extent IgG (Fig. 2 B) titers to PC-KLH,
suggesting the induction of anti-PC antibodies, which rep-
resent a family of autoantibodies including the natural anti-
PC antibody T15/EO6 (18, 25, 26). In contrast, mice immu-
nized only with PBS in adjuvant or with viable thymocytes
in adjuvant developed lower or undetectable antibody titers
to these antigens, respectively (Fig. 2, A and B).
Using competition immunoassay studies, we demon-
strated that the IgM binding of antisera from immunized
mice to OxLDL was nearly completely inhibited by both
OxLDL and MDA-LDL, but not native LDL, indicating
high specificity of the induced antibodies for oxidation-
specific epitopes (Fig. 3 A). PC-KLH also very efficiently
inhibited the IgM binding of the antisera to OxLDL,
whereas KLH alone did not, clearly demonstrating the
specificity of some of these antibodies for PC (Fig. 3 A).
Therefore, immunization with apoptotic cells induced an-
tibodies that are highly specific for epitopes derived from
phospholipid oxidation.
To compare the apparent binding affinities of the IgM
and IgG of antisera to OxLDL, we performed competition
immunoassays with these antisera using soluble OxLDL as a
competitor, and determined the dissociation constants (K
 
d
 
s)
of antibodies according to the Klotz method (23). The K
 
d
 
s
values for IgM and IgG binding were 1.5 
 
  
 
10
 
 
 
9
 
 mol/l
and 6.13 
 
 
 
 10
 
 
 
8
 
 mol/l, respectively (Fig. 3, B and C).
To further evaluate the immunogenicity of apoptotic cells,
we also immunized C57BL/6 mice with syngeneic apoptotic
thymocytes in PBS alone (i.e., without adjuvant), as well as
with viable thymocytes, or primary necrotic thymocytes gen-
erated by repeated freeze-thaw cycles (all without adjuvant).
Fig. 2 C demonstrates that even immunization with apoptotic
cells without adjuvant induced specific IgM antibodies against
oxidation-specific epitopes. However, in contrast with mice
immunized in the presence of adjuvant, in these mice, we did
not observe equivalent IgG responses (unpublished data).
Here as well, the specificity of the IgM binding to OxLDL
was confirmed by competition immunoassays and found to
be similar to the specificity of the antisera obtained from
aforementioned immunized NIH/Swiss-Webster mice (un-
published data). This response was specific for apoptotic cells
as immunization with neither viable thymocytes nor with
primary necrotic thymocytes induced such immune responses.
Thus, the process of programmed cell death seems to be a
requisite for the generation of immunogenic oxidation-spe-
cific epitopes, as primary necrotic cells or cellular components
leaking from damaged cells are not sufficient to induce hu-
moral responses against oxidation-specific epitopes.
Figure 2. Binding of immune sera to oxidatively modified epitopes.
Chemiluminescent immunoassay for the binding of IgM (A) and IgG (B)
from pooled immune sera of NIH/Swiss-Webster mice to indicated antigens.
NIH/Swiss-Webster mice were immunized in the presence of adjuvant
with the following: PBS, viable, normal thymocytes (Viable), and dexa-
methasone-treated apoptotic thymocytes (Apoptotic). (C) Binding of IgM
from pooled immune sera of C57BL/6 mice immunized in the absence of
adjuvant with the following: PBS, viable, normal thymocytes (Viable),
dexamethasone treated apoptotic thymocytes (Apoptotic), or suspension of
primary necrotic thymocytes generated by repeated freeze-thaw cycles
(Necrotic). Sera from NIH/Swiss-Webster and C57BL/6 mice were diluted
at 1:400 and 1:250 in PBS with 2% BSA, respectively, and IgM and IgG
bindings were measured as described in Materials and Methods. Data are
expressed as relative light units (RLU) per 100 ms. Each point is the mean
of triplicate determinations. 
Chang et al.
 
1363
 
Immune Sera Bind to Apoptotic Thymocytes via Oxidation-
specific Epitopes.
 
Next, we characterized the binding and
specificity of IgM and IgG from antisera to apoptotic cells.
Using deconvolution microscopy, we demonstrated spe-
cific binding of the immune sera to apoptotic cells (Fig. 4
A). Using immune sera from NIH/Swiss-Webster mice,
we noted both IgM and IgG binding to syngeneic apop-
totic cells seen as surface staining in a specific discrete pat-
tern (Fig. 4 A, green), consistent with membrane blebbing
that occurs with apoptosis (Fig. 4 A). The condensed nuclei
characteristic of apoptotic cells were detected by Hoechst
DNA staining (Fig. 4 A, blue). Preimmune sera did not
stain the apoptotic cells (Fig. 4 B), and immune sera did not
show reactivity with viable thymocytes (Fig. 4 C). More-
over, flow cytometry analyses demonstrated that the bind-
ing of these immune sera (IgM) was especially pronounced
in apoptotic thymocytes that were highly positive for PI
staining, indicating a later stage of apoptosis (Fig. 5 A, R3).
Because apoptotic cells generate OxPLs in their mem-
branes (Fig. 1), we tested whether the binding of immune
sera to apoptotic cells was in part due to binding to oxida-
tion-specific epitopes. We performed competition studies
of the IgM binding to apoptotic cells by flow cytometry
and determined the intensity of binding of the antisera after
preabsorption with indicated antigens. IgM binding of im-
mune sera to the gated cells (Fig. 5 A, R3) was strongly de-
creased by absorption with either OxLDL or MDA-LDL,
but not by native LDL, suggesting the importance of these
epitopes for the immunoreactivity of apoptotic cells (Fig. 5
C). Moreover, preabsorption of immune sera with both
OxLDL and MDA-LDL together led to an even stronger
and dose-dependent (
 
 
 
70%) inhibition of the binding to
apoptotic cells (Fig. 5 C). Thus, a large part of the apop-
totic cell–reactive IgM antibodies induced by immuniza-
tion with apoptotic cells bind via oxidation-specific epi-
topes. In similar studies, IgG binding to apoptotic cells was
also decreased by preabsorption of immune sera with either
OxLDL or MDA-LDL by 50%, and both OxLDL and
MDA-LDL together showed similar inhibition (
 
 
 
60%) as
was seen for the IgM binding to apoptotic cells (unpub-
lished data).
 
Splenocyte Cultures from Immunized Mice Secrete Both Th1
and Th2 Cytokines.
 
Because NIH/Swiss-Webster mice
immunized with apoptotic cells in the presence of adjuvant
developed high titers of IgG antibodies to oxidation-spe-
cific epitopes, we tested whether cellular immune responses
were induced in these mice as well. Therefore, we deter-
mined the cytokine secretion of splenocyte cultures ob-
tained from all immunized NIH/Swiss-Webster mice.
In the initial studies, splenocytes were cultured in the ab-
sence or presence of syngeneic apoptotic or viable thy-
mocytes to assess antigen-specific cytokine secretion. After
72 h of incubation, cytokine levels were measured in cul-
ture supernatants. Surprisingly, we found high cytokine se-
Figure 3. Competition immunoassay for immune sera binding
to OxLDL. (A) Competition immunoassay for binding of IgM
from a representative serum of NIH/Swiss-Webster mice im-
munized with apoptotic thymocytes as described in Materials
and Methods. The serum was diluted at 1:5,000 in PBS with
1% BSA and was incubated in the absence or presence of indi-
cated concentrations of native LDL, OxLDL, MDA-LDL, or
PC-KLH as competitors. Immune complexes were pelleted by
centrifugation, and supernatants were tested for binding of
IgM to OxLDL using chemiluminescent immunoassay. Com-
petition immunoassay for IgM (B) and IgG (C) from another
serum of NIH/Swiss-Webster mice immunized with apoptotic
thymocytes was performed to determine the binding affinity of
the antisera for OxLDL as described in Materials and Methods.
IgM binding was performed with 1:2,000 dilution and IgG
binding was performed with 1:300 dilution. Data are ex-
pressed as a ratio of the binding of serum in the presence of
competitor (B) over the binding in the absence of competitor
(Bo). Each point is the mean of triplicate determinations.
Figure 4. Immunofluorescence deconvolution microscopy of sera
binding to apoptotic cells: Pooled (IgM) or a representative (IgG) preimmune
and postimmune sera from NIH/Swiss-Webster mice immunized with
apoptotic thymocytes were diluted 1:200 in PBS with 1% BSA and incu-
bated with apoptotic or normal thymocytes. IgM or IgG binding to the
cells was detected by fluorescein-conjugated F(ab)2 fragments against
mouse IgM or IgG, respectively. (A) Note the marked binding of postim-
mune sera (green) to apoptotic thymocytes with their characteristic con-
densed, fragmented nuclei detected by Hoechst staining (blue). (B) Note
the negative staining of preimmune sera to apoptotic cells and (C)
postimmune sera to normal thymocytes. Bar, 5  m. 
Immune Reponse to Oxidation Epitopes of Apoptotic Cells
 
1364
cretion in the culture supernatants of immunized mice, but
not naive mice, even in the absence of any added antigenic
stimuli. We speculated that splenocytes themselves could
undergo apoptosis during the in vitro culture for 72 h,
which in turn could provide autoantigenic stimuli. Indeed,
splenocytes cultured for 72 h had definite evidence of
apoptosis, which was detected by DNA electrophoresis
documenting the typical ladder pattern of DNA fragmenta-
tion (unpublished data). Indeed, a similar degree of apopto-
sis was found in the splenocyte cultures obtained from all
three experimental groups.
As shown in Fig. 6, splenocyte cultures from mice im-
munized with apoptotic cells in the presence of adjuvant
showed both Th1 (IFN
 
 
 
) and Th2 (IL-5, IL-10, and IL-
13) cytokine release in the absence of added antigen. In
sharp contrast, splenocyte cultures from mice immunized
with PBS or viable thymocytes (which also contained adju-
vant) showed only very low levels of cytokine responses,
except for INF
 
 
 
 in the case of viable cells (even though
these cultures contained apoptotic cells as well). Additional
control cultures were stimulated with plate-bound anti-
CD3 to assess maximal nonspecific secretion of cytokines,
which yielded similar results among splenocyte cultures of
all three groups (unpublished data). These findings clearly
demonstrate that the resulting cytokine secretion was spe-
cific (with the possible exception of INF
 
 
 
, which may be
related in part to the adjuvant) for the immunization with
apoptotic cells, which induced strong cellular immune re-
sponses after immunization in the presence of adjuvant.
 
Apoptotic Cells with Oxidation-specific Epitopes Induce
Monocyte Adhesion to Endothelial Cells.
 
Monocytes are the
primary cells that are localized to chronic inflammatory le-
sions, including atherosclerosis. Initially, monocytes roll
along the vascular endothelium where they become acti-
vated by soluble or surface-bound chemokines. The acti-
vated monocytes adhere firmly to the endothelium and
transmigrate through the endothelial cell monolayer. This
occurs by the expression of adhesion molecules on overly-
ing endothelial cells induced by inflammatory stimuli. Ox-
LDL and OxPLs, such as POVPC and PEIPC, have been
shown to be capable of activating endothelial cells, leading
to monocyte-endothelial cell interaction (21, 27, 28).
To determine whether OxPLs that are present in the
context of apoptotic cells (14) may also exert such proin-
flammatory properties, we tested the ability of the apop-
totic cells to activate PAECs, as assessed by the ability of
PAECs to bind monocytes. Preincubation of PAECs with
apoptotic thymocytes led to the subsequent enhanced ad-
hesion of THP-1 cells, a human monocyte-like cell line
frequently used in these studies (24, 29), to the confluent
layer of PAECs (Fig. 7 A). In contrast, preincubation of vi-
able thymocytes did not lead to activation of the PAECs
(unpublished data). Furthermore, the monocyte adhesion
induced by apoptotic thymocytes was almost abolished by
the inclusion of EO6 during the preincubation, which
Figure 5. Flow cytometry analysis of sera binding to apoptotic thymocytes
and competition immunoassay for immune sera binding to apoptotic cells.
(A) Apoptosis-induced thymocytes were gated into three populations accord-
ing to forward scatter and the intensity of PI staining. (R1) Region 1: viable
cells or cells at the very early stage of apoptosis; (R2) region 2: cells at in-
termediate stage of apoptosis with dim PI staining, and (R3) region 3:
cells at later stage of apoptosis with shrunken cell size and bright PI staining.
(B) Pooled preimmune or postimmune sera from NIH/Swiss-Webster mice
immunized with apoptotic thymocytes were diluted at 1:500 in PBS with
1% BSA and tested for IgM binding to apoptotic thymocytes in region 3.
(C) Aliquots of diluted, pooled sera were incubated in the absence or
presence of OxLDL or MDA-LDL, or both as competitors at indicated
concentrations ( g/ml). After the incubations, immune complexes were
pelleted by centrifugation and supernatants were tested for IgM binding
to apoptotic thymocytes using flow cytometry. Mean fluorescence intensity
of binding of immune sera incubated in the absence (No) or presence of
competitors to the apoptotic thymocytes in region 3 was measured. Data dis-
play the inhibition of binding by competitors as percent of control in the ab-
sence of competitors and representative of three independent experiments.
Figure 6. Cytokine assay of splenocyte cultures. Splenocytes from each
mouse in each group of NIH/Swiss-Webster mice immunized with PBS,
viable cells, or apoptotic cells were harvested. Splenocytes were seeded at
5   106 cells per well into a 96-well tissue culture plate and were cultured
in triplicates in the absence of any added antigens for 72 h. After the incu-
bation, the amount of cytokine released into the supernatants was deter-
mined using chemiluminescent immunoassays as described in Materials
and Methods. Data reflect mean   SEM values of each group. *, P  
0.04 compared with groups immunized with either PBS or normal cells. 
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binds specifically to PC-containing OxPLs; however, note
that EO6 does not bind to lyso-PC (20). EO6 did not in-
hibit LPS-induced monocyte adhesion, implying that Ox-
PLs that were bound by EO6, such as POVPC or PEIPC,
were responsible for this effect. We also used HCAECs in a
similar study. As shown in Fig. 7 B, we observed a signifi-
cant ability of apoptotic cells to activate HCAECs to bind
THP-1 monocytes, and again viable thymocytes did not.
To directly address the mechanism by which apoptotic
cells induce monocyte–endothelial cell interaction, we
tested the expression of adhesion molecules on HCAECs
using flow cytometry. We did not observe enhanced ex-
pression of VCAM-1 and CS-1 fibronectin on the stimu-
lated endothelial cells (10). However, we did observe
HCAECs to secrete a significantly higher level of IL-8
when they were incubated with apoptotic cells compared
with that in the absence of stimulant or in the presence of
normal, viable cells (Fig. 8). Recently, IL-8 has been re-
ported to mediate firm monocyte adhesion to endothelial
cells even under flow conditions (30, 31). Furthermore, the
ability of PC-containing OxPLs to induce expression of
IL-8 in endothelial cells has been documented (21).
 
Discussion
 
Because the oxidative modification of LDL renders it
immunogenic and induces robust autoantibody responses
to oxidized lipids and/or lipid-protein adducts (11), and
because apoptotic cells display such oxidized moieties on
their plasma membranes (14), we investigated whether oxi-
dation-specific epitopes of apoptotic cells could also give
rise to similar autoimmune responses. Cell membranes
contain phospholipids with polyunsaturated fatty acids that
would be susceptible to oxidation when cells undergo
apoptosis. Indeed, a substantial body of evidence suggests
that cells undergoing apoptosis are under increased oxida-
tive stress, and that reactive oxygen species and/or OxPLs
mediate an apoptotic program and recognition of dying
cells by phagocytes (32–34).
In the present paper, we demonstrate directly that apop-
totic cells have an increased content of biologically active
OxPLs and that apoptotic cells bearing such oxidatively
modified moieties are immunogenic. Indeed, immuniza-
tion of mice with syngeneic apoptotic cells induced high ti-
ters of autoantibodies to various oxidation-specific epitopes
of OxLDL, whereas immunization with neither viable,
normal cells nor primary necrotic cells did (Fig. 2). Thus,
the process of apoptosis is requisite for the generation
of immunostimulatory, oxidation-specific neoepitopes that
induce such autoimmune responses. Reciprocally, we also
demonstrate that immune sera bind to the cells at later
stages of apoptosis, in large part through the recognition of
oxidation-specific epitopes, implying that these epitopes
can also serve as antigenic determinants for the recognition
of apoptotic cells by autoantibodies. Although it has been
demonstrated previously that syngeneic apoptotic cells can
be immunogenic under appropriate conditions, our data
demonstrate that, remarkably, up to 70% of the IgM from
Figure 7. Monocyte adhesion to endothelial cells induced by apoptotic
cells. (A) The ability of apoptotic cells to stimulate endothelial cells for
monocyte binding was tested. Porcine aortic endothelial cells (PAECs)
were incubated for 4 h at 37 C with culture media alone or EO6 anti-
body in the absence or presence of apoptotic thymocytes (5   106 per
well) generated by incubation with serum-starved media for 18 h as stim-
ulant. 100 ng/ml LPS was used as positive control. For these experiments,
EO6 antibody was obtained from the culture supernatant of EO6 hybrid-
oma that was maintained under LPS-free culture condition. After the incuba-
tion, stimulants were washed off with PBS, and PAECs were incubated with
THP-1 cells for 30 min at 37 C. Nonadherent THP-1 cells were removed by
washing, and the number of adherent THP-1 cells was determined in 10 
high-power field per well. The results of four to six separate wells were
averaged for each experiment. Data reflect mean   SEM values of data
from three different experiments. (B) Human coronary artery endothelial
cells (HCAECs) were tested. In this experiment, viable, normal thy-
mocytes were used as another control.
Figure 8. Apoptotic cells stimulate endothelial cells to secrete IL-8.
HCAECs were incubated for 4 h at 37 C with culture media alone; viable,
normal thymocytes; or apoptotic thymocytes induced by UV irradiation as
stimulant. Apoptotic thymocytes themselves did not release IL-8. 200 ng/ml
LPS was used as a positive control. After the incubation, IL-8 in the su-
pernatants was determined as described in Materials and Methods. Data
represent the mean   SEM of quadruplicates. 
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such murine sera (and 
 
 
 
60% of IgG) are directed at oxida-
tion-specific epitopes of apoptotic cells. These data demonstrate
that such oxidation-specific epitopes are immunodominant
neoepitopes, just as they are when LDL undergoes oxida-
tive modification.
Apoptosis is a physiological form of cell death responsible
for removal of unwanted cells in diverse physiological and
pathological processes (7). Normally, apoptotic cells are
cleared swiftly by phagocytes without inciting inflammatory
or immune responses. However, under certain conditions,
the pathological accumulation of increased numbers of apop-
totic cells may incite inflammatory and immune responses
(6, 7, 35). Indeed, an increased rate of formation, and/or a
defective clearance of apoptotic cells has been postulated as
a potential mechanism that may be responsible for autoim-
mune responses (7, 36). The systemic exposure of apoptotic
cells in mice by immunization with syngeneic apoptotic
cells, but not viable cells, has been shown to initiate autoan-
tibodies to apoptotic cells or autoantigens, such as ssDNA
and cardiolipin (4, 5). Moreover, studies have demonstrated
that humans and mice with C1q deficiency, or mice lacking
function of the c-mer membrane tyrosine kinase show de-
fective clearance of apoptotic cells, and develop a lupuslike
syndrome as well as anti-DNA antibodies (37–39). Simi-
larly, mice deficient in MFG-E8, which led to impaired up-
take of apoptotic cells, were also noted to have autoanti-
body generation and glomerulonephritis (40).
Therefore, we speculate that in conditions that lead to
defective clearance of apoptotic cells and advancement to
later stages of apoptosis, novel antigenic determinants are
generated, which in turn stimulate such autoimmune re-
sponses. Consistent with this, autoantibodies found in pa-
tients with SLE and aPL syndrome have been shown to
recognize apoptotic cells as well as OxLDL (1–3, 41). In
collaboration with others, we demonstrated enhanced ti-
ters of autoantibodies to oxidation-specific epitopes of
OxLDL in patients with SLE (42), even in young children
who have no evidence for clinical cardiovascular disease
(43). However, the precise nature of the antigenic deter-
minants of apoptotic cells that lead to such autoimmunity
has not yet been clearly elucidated. Several studies have
suggested that the autoantigens inducing autoimmune re-
sponse during apoptosis might be structurally modified
proteins, generated as a result of proteolytic cleavage and/
or phosphorylation (36). Furthermore, earlier studies in
our laboratory have shown that many so-called aPLs are in
fact directed against OxPL and/or oxidized lipid-protein
adducts, but not against non-OxPLs (44–46). These observa-
tions support our demonstration that oxidative modifica-
tion serves to generate antigenic determinants. Another
group also has shown that monoclonal anticardiolipin
antibodies established from the (NZWxBXSB)F1 mouse
model of aPL syndrome cross-reacted with OxLDL (47),
and we too have made similar observations (unpublished
data). Thus, our present studies provide direct evidence
that as a consequence of apoptosis, oxidative modification
of lipid components generates neoself-oxidation–specific
epitopes, which in turn lead to an autoimmune response
and serve as antigenic determinants targeted by the au-
toantibodies.
As noted in the Introduction, EO6 is a classic natural an-
tibody specific to PC, and we have demonstrated previously
that they bind specifically to apoptotic cells, but not to via-
ble cells (14, 18). In mice, such natural anti-PC antibodies
provide a first line of innatelike immune defense against a
variety of microbial infections, such as 
 
S. pneumoniae
 
 (19),
and mice deficient in T15 antibodies are uniquely suscepti-
ble to 
 
S. pneumoniae
 
 infection (48). Similar antibodies have
been demonstrated in the plasma of healthy humans as well
(49, 50). Because these germline encoded antibodies are
naturally selected and are present within the first week of
life even in mice grown in germ-free conditions (51), we
have postulated that they are positively selected by PC ex-
posed by oxidized phosphatidylcholine present on apoptotic
cells and/or oxidized lipoproteins (18). In the present paper,
we directly demonstrate that apoptotic cells can stimulate
such anti-PC antibodies (Figs. 2 and 3). Therefore, we pro-
pose that oxidative modification of phosphatidylcholine in
the membranes of cells undergoing apoptosis reveals PC as a
natural antigenic determinant, which in turn stimulates B
cell immune responses to PC. Furthermore, these data sug-
gest that apoptotic cells bearing PC might play a role in the
ontogeny of anti-PC antibodies.
The functional capacity of the immune system represents
a sophisticated balance between the defense from invading
infectious pathogens, and the avoidance of autoreactivity
that can damage the host. Certainly, some B-1 cell–derived
IgM antibodies may exert adverse effects (52). However, it
is now also generally accepted that certain aspects of au-
toimmunity may occur in, and perhaps even contribute to,
health (53). Several studies suggest that the recognition of
IgM anti-PC antibodies to apoptotic cells is important in
clearance of apoptotic cells as well as immune modulation.
One consequence that occurs as a result of induction of
apoptosis is the generation of enhanced oxidative mecha-
nisms, resulting in enhanced content of oxidized phos-
phatidylserine (34). These likely form the important recog-
nition signals for binding to the phosphatidylserine receptor
on macrophages (34). We now add the generation of oxi-
dized phosphatidylcholines in apoptotic cells as well. The
presence of such PC-containing OxPLs are known ligands
mediating CD36 binding (16, 17) and explains why anti-
body EO6 inhibits binding and uptake of apoptotic cells by
macrophages (14).
In addition, our studies demonstrated the enhanced gen-
eration of lyso-PC (Fig. 1). The latter may occur as oxidized
phosphatidylcholines contain oxidized sn-2 fatty acids that
become preferred substrates for several PLA
 
2
 
-type enzymes,
which lead to lyso-PC generation. A recent paper by Kim
et al. has shown that human natural anti-PC IgM antibodies
from sera of normal individuals bind to late apoptotic cells
through recognition of lyso-PC. Subsequently, their bind-
ing recruited C1q on the cell surface leading to C3 activa-
tion (54), which in turn would enhance clearance of
opsonized apoptotic cells (55). Moreover, because macro-
phages or dendritic cells phagocytosing apoptotic cells op- 
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sonized with C3 produce immunosuppressive cytokines,
complement activation mediated by these IgM antibodies
may play a crucial role in modulating the immune response
(56, 57). In our paper, we directly demonstrate another po-
tential protective capacity of such natural IgM anti-PC anti-
bodies, such as EO6, which have the capacity to block
proinflammatory properties (Fig. 7) and, thus, may represent
another conserved arc of innate immunity that is recruited
to dampen inflammatory responses. In a similar manner,
EO6 binds to apoptotic cell blebs and abrogates some of
their proinflammatory properties (58). Therefore, the possi-
ble scenario would be that these anti-PC antibodies stimu-
lated by PC exposed in the context of apoptotic cells may
confer protection to the host from more devastating inflam-
matory and autoimmune responses by promoting the clear-
ance of dying cells and also by modulating these responses.
Alternately, it should be pointed out that autoimmune
responses to PC and other oxidation-specific epitopes
could bring harmful outcomes, in particular in the presence
of other proinflammatory stimuli. As shown in Fig. 2 B,
immunization of apoptotic cells in the presence of Freund’s
adjuvant, a potent proinflammatory stimulant, induced
high titers of IgG to oxidation-specific epitopes, but such
IgG immune responses were not observed in the absence of
the adjuvant. Were such IgG immune responses to occur in
vivo as a consequence of inflammatory stimuli, this could
lead to the generation of IgG responses, engagement of IgG
immune complexes to macrophage Fc
 
 
 
 receptors, and the
production of inflammatory cytokines. This phenomenon
may play a role in the pathogenesis of autoimmune diseases
when the defective clearance, and hence the pathological
accumulation of apoptotic cells, occur coupled with vari-
ous proinflammatory stimuli, such as infectious agents or
toxic oxidized lipids (i.e., as found in the atherosclerotic
plaque. Indeed, it was recently shown that mice with
impaired clearance of apoptotic cells due to Fas ligand de-
ficiency, when crossed into 
 
apoE
 
   
 
 mice, developed accel-
erated atherosclerosis and attendant autoimmune phenome-
non,  including enhanced autoantibody titers to epitopes
found in OxLDL (59).
Atherosclerosis is now considered a chronic inflamma-
tory disease of the vascular wall (8, 60) and there is a sub-
stantial body of evidence that OxPLs in OxLDL induce
proinflammatory responses promoting the atherogenic pro-
cess (10). PC-containing OxPLs activate endothelial cells
to recruit monocytes into the vascular wall and stimulate
them by regulating inflammatory gene expression (10, 61)
OxLDL with such OxPLs accumulate in atherosclerotic le-
sions (13, 27). Furthermore, there is also a marked accumu-
lation of apoptotic cells in atherosclerotic lesions (62). In
the present paper, we demonstrate directly that the ability
of apoptotic cells to activate endothelial cells to tightly bind
monocytes is completely abrogated by EO6. This implies
that the enhanced content of biologically active oxidized
phosphatidylcholines in apoptotic cells activates endothelial
cells to induce adhesion and recruitment of monocytes.
Adhesion of monocytes to endothelial cells is a crucial,
rate-limiting step in the pathogenesis of atherosclerosis in
particular, and an initial process for the recruitment of mac-
rophages into damaged tissues and inflammatory lesions in
general. In this paper, we demonstrated further that such
monocyte–endothelial interaction can be mediated in part
through IL-8. IL-8 is a CXC chemokine produced by en-
dothelial cells that has recently been reported to mediate
firm adhesion of monocytes to endothelial cells, even un-
der flow conditions (30, 63). Oxidized PAPC (1-palmi-
toyl-2-arachidonyl-sn-glycero-3-phosphorylcholine), and
specifically isomers of PEIPC as well as POVPC (products
readily bound by EO6), are known to be present in the
atherosclerotic lesion and can induce such IL-8 expression
(21). In support of an important role of IL-8 is the observa-
tion that deletion of the IL-8 receptor in 
 
LDLR
 
   
 
 mice
markedly decreases atherosclerosis (64).
Consistent with our finding, recent studies have demon-
strated that apoptotic cells have the ability to provoke an
inflammatory response by unidentified proinflammatory
mediators (65, 66), suggesting that under certain condi-
tions, apoptotic cells themselves may provide endogenous
“danger signals” triggering an inflammatory response. Lau-
ber et al. have shown recently that apoptotic cells release
lyso-PC to serve as a chemotactic signal that induces attrac-
tion of monocytic cells to apoptotic cells, presumably to
ensure their efficient removal (67). Lyso-PC released from
OxLDL has been demonstrated already to be a potent che-
motactic factor for monocytes and T cells (68, 69). Because
EO6 does not bind to lyso-PC (20), yet abrogated the abil-
ity of apoptotic cells to induce firm monocyte adhesion to
endothelial cells (Fig. 7), our findings suggest that oxidized
phosphatidylcholines present on apoptotic cells are also
prominent mediators that lead to recruitment of inflamma-
tory cells. Thus, they too serve as endogenous inflamma-
tory danger signals, ensuring an ensuing host response that
could play an important role in limiting the danger posed
by the accumulated dying cells.
It is tempting to postulate that oxidative modification of
lipids in cells that occur during apoptosis is a novel mecha-
nism by which apoptotic cells could promote autoimmune
and proinflammatory responses. Alternately, such responses
may be protective by enhancing the clearance of apoptotic
cells and/or repression of such proinflammatory response.
However, they could also participate in the pathology of a
variety of diseases in which the abnormal accumulation of
such cells occurs, for instance, in the atherosclerotic lesion
(62) and other chronic inflammatory diseases, including au-
toimmune disorders such as SLE (7).
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